No Detail Found!

CBX2 Expression in Colorectal Mucosa-adenoma-adenocarcinoma Sequence

Author(s)
Bangting Wang Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai, China
Meina Huang State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China
Xin Wang State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China
Yujen Tseng Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai, China
Feifei Luo Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai, China
Jie Liu Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai, China
Abstract
Objective: To investigate the expression of chromobox 2 (CBX2) in colorectal adenoma (CRA) and colorectal cancer (CRC), and analyse its correlation with various clinicopathological parameters. Study Design: Observational study. Place and Duration of Study: Pathology Department, Huashan Hospital, Fudan University, from December 2019 to December 2020. Methodology: The mRNA level of CBX2 in colorectal mucosa, CRA and CRC was evaluated in gene expression pro ling interactive analysis (GEPIA) and gene expression omnibus (GEO) dataset, then veri ed by quantitative real-time PCR (qRT-PCR). CBX2 expression by immunohistochemistry was determined in 122 samples, then its correlation was analysed with various clinicopathological parameters. Diagnostic value of CBX2 was estimated by the receiver operating characteristic curve (ROC). Prognostic value of CBX2 mRNA expression was evaluated via the Kaplan-Meier method in GEPIA. Results: CBX2 expression rate in CRC (89.8%) was greater than adenoma (37.74%) and mucosa (20%). CBX2 protein levels were highest in adenocarcinoma and lowest in mucosa with intermediate level in adenoma. The area under curve (AUC) of CBX2 was 0.810 and 0.734, respectively, in distinguishing CRA from mucosa and CRC from CRA. CBX2 hyperexpression was not signi cantly correlated with clinicopathological variables, either in CRA or CRC. Kaplan-Meier survival analysis revealed that CBX2 mRNA hyperexpression was not associated with overall survival (OS) of CRC. Although the disease-free survival (DFS) of high CBX2 patients was shorter than those with low expression, but no obvious signi cance was found in colon adenocarcinoma (COAD, p=0.052) and rectal adenocarcinoma (READ, p=0.097). Conclusion: CBX2 expression progressively increased in the sequence of mucosa-adenoma-carcinoma, which may be used as a diagnostic biomarker and therapeutic target for CRA and CRC.
Publication Details
Page(s) 1051-1056
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 31, Issue: 9, Year: 2021

Request the full text from PASTIC

Keywords
Biomarker, colorectal cancer, Colorectal Adenoma, CBX2
0

Citations

0

Downloads

85

Views